Reuters logo
BRIEF-Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial
October 10, 2017 / 10:48 AM / 14 days ago

BRIEF-Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial

Oct 10 (Reuters) - Vical Inc

* Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial

* Vical Inc - ‍Astellas Pharma Inc. expects top-line data to be available in Q1 of 2018​

* Vical Inc - continues to provide Astellas with development, regulatory and manufacturing support for program​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below